Apellis Pharmaceuticals Inc (APLS) stock saw a modest uptick, ending the day at $36.73 which represents a slight increase of $1.10 or 3.09% from the prior close of $35.63. The stock opened at $36.24 ...
The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...
A real-world study of pegcetacoplan for treatment of geographic atrophy showed significantly better outcomes than the pivotal clinical trials in patients who had symptomatic vision loss.